![thumbnail image](https://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png)
![broken image](http://user-assets.sxlcdn.com/images/315509/Fo7OSkXOifooK4qlDEl3GJnEZDke.png?imageMogr2/strip/auto-orient/thumbnail/300x300>/format/png)
POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
- Financing led by LongRiver Investments with participation by new and existing global...- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the...Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to...More Posts
Company
Shanghai
Room 2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Room 606-7, St. George's Building, 2 Ice House Street, Central, Hong Kong
US
2735 Sand Hill Road, Suite 210
Menlo Park, CA 94025
copyright © 2018 Lilly Asia Ventures all rights reserved.
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
https://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png